Ortenau Klinikum

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Acute myeloid leukaemia4 trials
• Hodgkin lymphoma3 trials
• Myelodysplastic syndromes3 trials
• Acute lymphoblastic leukaemia1 trial
• Diffuse large B-cell lymphoma1 trial
• Follicular lymphoma1 trial
• Ovarian cancer1 trial

Phase

• Phase 36 trials
• Phase 24 trials

Status

• Recruiting5 trials
• Active, not recruiting3 trials
• Completed2 trials

Lead sponsor

• University Of Cologne3 trials
• Stichting Hemato-Oncologie voor Volwassenen Nederland2 trials
• University of Ulm2 trials
• AGO Study Group1 trial
• Goethe University1 trial
• and 1 more

Running trials

• Recruiting

  PREFer

  NCT06916416· Phase 2· University Of Cologne· Source

• Recruiting

  Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT07197307· Phase 2· Universität Münster· Source

• Active, not recruiting

  Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma

  NCT04837859· Phase 2· University Of Cologne· Source

• Recruiting

  Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT

  NCT06061094· Phase 2· Goethe University· Source

• Recruiting

  Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

  NCT05009082· Phase 3· AGO Study Group· Source

• Recruiting

  Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

  NCT04628026· Phase 3· University of Ulm· Source

• Active, not recruiting

  A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

  NCT04027309· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

  NCT03839771· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Completed

  HD21

  NCT02661503· Phase 3· University Of Cologne· Source

• Completed

  Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)

  NCT02013648· Phase 3· University of Ulm· Source